Bristol Myers Squibb announced that it will deploy its second NVIDIA DGX SuperPOD, built from eight DGX Vera Rubin NVL72 systems. The company says the platform will provide every scientist with access to a unified AI environment for prediction, model training and agentic workflows across the drug-discovery pipeline. It will include NVIDIA’s BioNeMo Agent Toolkit for biological AI. NVIDIA states that the new infrastructure can deliver up to 10x the performance per megawatt of the infrastructure it replaces. The announcement follows BMS’s existing large AI cluster investment in life sciences.
No heat snapshots are available in the last 24 hours.